Kuopio, Finland – April 13, 2026 Experimentica Ltd., a trusted partner in preclinical drug development for ocular diseases, is pleased to announce the appointment of Teija Parkkari as Director of Business Development, effective April 13, 2026.

Dr. Parkkari brings over 15 years of experience spanning academia, pharmaceutical, and biotechnology organizations, with expertise in neuroscience and rare diseases. Prior to joining Experimentica, she held senior positions at Roche and Charles River Laboratories, contributing to R&D operations, global client portfolio management, and early-stage clinical development strategy across Europe and the USA. 

In her new role, Teija will lead key account management, RFP and proposal processes, and the development of commercial infrastructure across Experimentica’s operations. Her appointment reflects the company’s commitment to strengthening its client relationships and accelerating growth across its sites in Finland and Lithuania. 

"Teija brings deep CRO expertise and a proven track record of managing complex client relationships, further strengthening our business development team. Her experience will be instrumental as we accelerate growth and continue delivering high-quality preclinical services to our customers."

Guillaume Demarne,

Experimentica Ltd.

“Joining Experimentica is an exciting opportunity. The team has built a strong scientific reputation and a growing commercial presence. I look forward to contributing to that momentum and working closely with clients to support their drug development programs.” 
Teija Parkkari, Director of Business Development, Experimentica Ltd.

For more information about Experimentica Ltd. and its latest developments, please contact:

Guillaume Demarne, PharmD
Chief Business Officer
guillaume.demarne@experimentica.com
+33 7 83 55 69 52

About Experimentica Ltd.

At Experimentica, we help drug development teams advance safe and effective ocular therapies from discovery to the clinic. Our preclinical ophthalmic experts work closely with customers throughout their projects, offering tailored scientific guidance and support. With state-of-the-art technologies, proprietary algorithms, and AI-driven analysis, we deliver comprehensive data and actionable insights to accelerate decision-making and development.

About Teija Parkkari

Dr. Parkkari has over 15 years of experience in drug development across academia and the pharmaceutical and biotechnology industries, with a focus on neuroscience and rare diseases. She has been actively involved in business development, R&D operations, and strategic portfolio management across global pharmaceutical companies, CROs, and academic organizations in Europe and the USA.

Guillaume Demarne

Guillaume Demarne

, PharmD

Chief Business Officer